Amir Rad

Avhandlingen er tilgjengelig her! / The doctoral thesis is available here!

Prøveforelesning over oppgitt emne starter kl. 10.15 / The trial lecture starts at 10.15
Tittel/Title: «The future of cervical cancer screening: Alternative strategies for optimizing high-performance tests to reduce cervical cancer burden. »
Prøveforelesningen strømmes her / The trial lecture will be streamed here

Disputasen starter kl. 12.15 / The defense starts at 12.15
Disputasen strømmes her / The defense will be streamed here

De som ønsker å opponere ex auditorio kan sende en e-post til leder av disputasen innen kl. 13:00 disputasdagen: christine.rinaldo@uit.no
If you want to oppose ex. auditorio, send an e-mail to the leader of the defence before 13:00 on the day of the defence: christine.rinaldo@uit.no

Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis

Scientists and healthcare professionals are continuously striving to prevent and treat cancer, including cervical cancer, which is the fourth most common cancer among women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) can cause cervical cancer, which typically progresses through a series of precancerous lesions. To prevent cervical cancer, vaccination and screening are crucial measures. While both cervical cytology examination and HPV tests are commonly used to screen for cervical cancer, cytology-based screening has low sensitivity and is being replaced by HPV-based tests.
In this study, the detectability of high-risk HPV types and performance in triage of women with minor cervical lesions were compared using the HPV DNA test and the HPV mRNA test. Additionally, the long-term risk predictability for high-grade cervical lesions was evaluated using an HPV mRNA test.
The findings indicated that the HPV mRNA test had similar detectability and efficacy in triage of minor cytological lesions compared to the HPV DNA test, while requiring less healthcare utilization. Furthermore, the HPV mRNA test was shown to be a reliable screening test for predicting high-grade cervical lesions in the long-term.

Veiledere/ Supervisors:
Hovedveileder/Main supervisor:
Professor Maja-Lisa Løchen, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.
Biveiledere/supervisors:
Ph.d. Sveinung Wegeland Sørbye, Universitetssykehuset Nord-Norge.
Professor Tormod Ola Brenn, Institutt for samfunnsmedisin, Det helsevitenskapelige fakultetUiT Norges arktiske universitet.
Forsker Sweta Tiwari, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.

Bedømmelseskomité/Defensecomitee:
Ph.d. Miriam Elfström, Karolinska Institutet  – 1. opponent.
Professor Olav Karsten Vintermyr, Haukeland Universitetssykehus / Universitetet i Bergen– 2. opponent.
Professor Inigo Martinez, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité.

Disputasleder/ Leader of defense:
Professor II Christine Hanssen Rinaldo, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.